JMP Securities analyst Reni Benjamin has maintained their neutral stance on ACET stock, giving a Hold rating yesterday.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Reni Benjamin’s rating is based on a thorough analysis of Adicet Bio’s current clinical trial progress and financial standing. The company has enrolled patients in its ADI-001 and ADI-270 Phase 1 trials, which are on track to deliver initial results in the first half of 2025. Despite these developments and the receipt of fast-track designation from the FDA, the analyst maintains a neutral stance due to uncertainties surrounding the clinical outcomes.
Furthermore, while Adicet Bio has a solid cash position of approximately $175 million, the valuation of its shares is deemed fair at this point. The potential for new data from trials targeting lupus nephritis and clear cell renal cell carcinoma could lead to significant advancements; however, until these data are available and confirm the efficacy of their engineered gamma-delta T cells, the recommendation remains cautious.